Significant and meaningful chorea control across multiple endpoints1,2

AUSTEDO reduced total maximal chorea (TMC) score by 4.4 points from baseline (P<0.0001)1

FIRST-HD Primary Endpoint: Change in TMC Score From Baseline to Maintenance Therapy (N=90, ITT)1,3

FIRST-HD: Total maximal chorea (TMC)     score from baseline to     maintenance therapy     (N=90, ITT), >2x improvement in TMC score seen with AUSTEDO vs placebo. FIRST-HD: Total maximal chorea (TMC)     score from baseline to     maintenance therapy     (N=90, ITT), >2x improvement in TMC score seen with AUSTEDO vs placebo.

>2x IMPROVEMENT

in TMC score seen with AUSTEDO vs placebo

The TMC score quantifies choreic movements of the face, mouth, trunk, and both arms and both legs, resulting in an overall score for the 7 regions that is based on independent visual reviews.3

  • ≥6-point improvement in TMC score was achieved in 33% of patients treated with AUSTEDO compared to 2% of patients treated with placebo3

AUSTEDO reduced total motor score (TMS), improving control of motor function2

FIRST-HD: Change in TMS From Baseline to Maintenance Therapy (N=90, ITT)3

FIRST-HD: Change in total motor score (TMS)     from baseline to     naintenance therapy     (N=90, ITT), >2x reduction in total motor function impairment with AUSTEDO vs placebo (P=0.0002). FIRST-HD: Change in total motor score (TMS)     from baseline to     naintenance therapy     (N=90, ITT), >2x reduction in total motor function impairment with AUSTEDO vs placebo (P=0.0002).

>2x REDUCTION

in total motor function impairment with

AUSTEDO vs placebo (P=0.002)

TMS confirms the clinical relevance of the change in TMC. TMS assesses all domains of motor dysfunction in HD, including chorea, dystonia, initiation of voluntary movement (dysarthria, tongue protrusion, finger tapping, hand pronation, and supination of hands), gait, and balance.3

AUSTEDO reduced disability and improved physical function2,3

FIRST-HD: SF-36 Physical Functioning Scale Score in FIRST-HD (N=90, ITT)

SF-36 physical     functioning scale score in FIRST-HD (N=90, ITT), 4.3 point mean difference vs placebo (P=0.03).

The physical functioning portion of the SF-36 assesses patients’ reported ability to perform routine physical activities such as walking, climbing stairs, bathing, or dressing.3

  • Patients taking AUSTEDO achieved greater improvement in the SF-36 Physical Functioning Scale Score at 12 weeks vs placebo (0.74 vs -3.61)2,3

Treatment success recognized by both physicians and patients1-3

The first and only therapy to have more physicians and patients who rated overall HD chorea symptoms as “much improved” or “very much improved” as measured by CGIC and PGIC

FIRST-HD: Global Impression of Change at the End of Treatment for AUSTEDO Compared to Placebo (N=90, ITT)

FIRST-HD: Global Impression of Change (GIC): Overall HD symptoms rated as "much improved" or "very much improved" at Week 12 (secondary endpoint), 42% of physicians observed treatment success (P=0.002), 51% of patients observed treatment success (P=0.002). FIRST-HD: Global Impression of Change (GIC): Overall HD symptoms rated as "much improved" or "very much improved" at Week 12 (secondary endpoint), 42% of physicians observed treatment success (P=0.002), 51% of patients observed treatment success (P=0.002).

*Treatment success was defined as “much improved” or “very much improved” at Week 12.3

CGIC and PGIC are single-item questionnaires that ask the patient and physician to assess overall HD symptoms on a 7-point scale—from “very much worse”(-3) to “very much improved”(+3). Treatment success was defined as “much improved” or “very much improved” at Week 12.3

  • “Minimally improved,” defined as slightly better functioning from baseline, answers were also observed but not included in this measure
  • Patients whose status at Week 12 was not known were not included in this measure
FIRST-HD study design

FIRST-HD was a randomized, 12-week, placebo-controlled study in patients with chorea associated with HD. Patients were randomized to receive AUSTEDO (n=45) or placebo (n=45). The mean age of patients taking AUSTEDO was 55.4 years (vs 52.1 years with placebo). 62% of AUSTEDO patients were concomitantly taking antidepressants (vs 53% with placebo). The mean dose of AUSTEDO taken by patients at the end of the titration period was 40 mg/day. The primary efficacy endpoint was the treatment effect of AUSTEDO vs placebo, as measured by the TMC score, an item of the Unified Huntington’s Disease Rating Scale, from baseline to maintenance. On this scale, chorea is rated from 0 to 4 (with 0 representing no chorea) for 7 different parts of the body. The total score ranges from 0 to 28. The combined group mean TMC score at baseline was 12.7.1-3

SF-36, Short Form (36) Health Survey.

REFERENCES: 1. AUSTEDO® (deutetrabenazine) tablets current Prescribing Information. Parsippany, NJ, Teva Neuroscience, Inc. 2. Frank S, Testa CM, Stamler D, et al.; Huntington Study Group. Effect of deutetrabenazine on chorea among patients with Huntington disease: a randomized clinical trial. JAMA. 2016;316(1):40-50. 3. Data on file. North Wales, PA: Teva Neuroscience, Inc.